TGFB1 and cancer: EHMT2 inhibition enhanced NK cell-mediated cytotoxicity by upregulating AZGP1 and NKG2D ligands, reducing TGF-β1 levels in cancer cells, and relieving TGF-β1-mediated suppression of NK cell function and migration.